Search Results 2561 – 2580 of 3236
Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV
https://clinicalinfo.hiv.gov/node/9343
Human Papillomavirus Disease
https://clinicalinfo.hiv.gov/node/9345
Appendix C: Antiretroviral Medications That Can Be Switched Temporarily If Unable to Access Certain Formulations
https://clinicalinfo.hiv.gov/node/9346
Maraviroc (Selzentry, MVC)
https://clinicalinfo.hiv.gov/node/9347
Disseminated Mycobacterium avium Complex Disease
https://clinicalinfo.hiv.gov/node/9348
Mycobacterium avium Complex Disease
https://clinicalinfo.hiv.gov/node/9349
Fosamprenavir
https://clinicalinfo.hiv.gov/node/9350
Varicella-Zoster Virus Disease
https://clinicalinfo.hiv.gov/node/9353
Preventing HIV Transmission During Infant Feeding
https://clinicalinfo.hiv.gov/node/9354
Appendix D. Financial Disclosures
https://clinicalinfo.hiv.gov/node/9355
Appendix A: Sample Short Intake Form for People With HIV Who Are Seeking Care
https://clinicalinfo.hiv.gov/node/9356
Nevirapine (Viramune, NVP)
https://clinicalinfo.hiv.gov/node/9357
Table 3. Indications for Discontinuing and Restarting Primary and Secondary Prophylaxis (or Chronic Maintenance Therapy) for Selected Opportunistic Infections in Adults and Adolescents with HIV
https://clinicalinfo.hiv.gov/node/9358
Special Populations: Early (Acute and Recent) HIV Infection
https://clinicalinfo.hiv.gov/node/9359
Antiretroviral Pregnancy Registry
https://clinicalinfo.hiv.gov/node/9361
Rilpivirine (Edurant, RPV)
https://clinicalinfo.hiv.gov/node/9363
Lipodystrophies and Weight Gain
https://clinicalinfo.hiv.gov/node/9364
Financial Disclosure
https://clinicalinfo.hiv.gov/node/9369
Tenofovir Alafenamide (Vemlidy, TAF)
https://clinicalinfo.hiv.gov/node/9370
Syphilis
https://clinicalinfo.hiv.gov/node/9371